z-logo
Premium
The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism
Author(s) -
Möllmann Julia,
Kahles Florian,
Lebherz Corinna,
Kappel Ben,
Baeck Christer,
Tacke Frank,
Werner Christian,
Federici Massimo,
Marx Nikolaus,
Lehrke Michael
Publication year - 2017
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12839
Subject(s) - roflumilast , steatohepatitis , endocrinology , medicine , insulin resistance , creb , weight loss , type 2 diabetes , mitochondrial biogenesis , protein kinase a , glucose uptake , chemistry , fatty liver , insulin , kinase , diabetes mellitus , mitochondrion , copd , obesity , biochemistry , disease , transcription factor , gene
Aims To investigate the metabolic effects of the phosphodiesterase‐4 (PDE4) inhibitor roflumilast, a clinically approved anti‐inflammatory drug used for the treatment of chronic obstructive pulmonary disease. Materials and methods The metabolic effects of roflumilast were investigated in C57BL/6J mice, fed a high‐fat Western‐type diet and treated with or without roflumilast for a period of 12 weeks. Results Roflumilast led to a marked reduction in body weight gain, which became apparent in the second week after treatment initiation and was attributable to a pronounced increase in energy expenditure. Furthermore, roflumilast improved glucose tolerance, reduced insulin resistance and diminished steatohepatitis in mice. Mechanistically, this was associated with hepatic protein kinase A (PKA) and cAMP response element binding protein (CREB) activation, leading to peroxisome proliferator‐activated receptor gamma coactivator‐1α (PCG‐1α)‐dependent induction of mitochondrial biogenesis. Consistently, roflumilast increased the cellular respiratory capacity of hepatocytes in a PKA‐dependent manner. Conclusion Roflumilast‐dependent PDE4 inhibition is a new target for weight loss strategies, especially in conditions of associated comorbidities such as insulin resistance and non‐alcoholic steatohepatitis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here